RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for low blood counts after CAR T-Cell therapy?
Disease control Recruiting nowThis study tests a drug called emapalumab to see if it can safely help people whose blood cell counts stay dangerously low after CAR T-cell therapy for certain lymphomas. About 32 adults who have already received standard CAR T-cell therapy will take part. The goal is to find out…
Matched conditions: RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New immune cell therapy tracks itself in the body to fight lymphoma
Disease control Recruiting nowThis early study tests a new type of cell therapy for people with follicular lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to target cancer cells and also carry a tracking tag that can be see…
Matched conditions: RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC